文献速递头颈部肿瘤放疗

局部晚期鼻咽癌诱导化疗后缩小靶体积与降低放疗剂量后的局部区域控制与轻度晚期毒性:2期研究10年结果

Locoregional Control and Mild Late Toxicity After Reducing Target Volumes and Radiation Doses in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy: 10-Year Results of a Phase 2 Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-04-05

这项前瞻性2期研究纳入112例局部晚期鼻咽癌患者,接受2周期诱导化疗后同步放化疗,按诱导化疗后肿瘤范围缩小靶体积并降低剂量。中位随访125.95个月,10年局部区域无复发生存率89.0%、无远处转移生存率83.3%、总生存率75.9%;局部复发8例均为野内,区域复发6例中4例野内、1例边缘、1例野外;最常见晚期毒性为1-2级皮下纤维化、听力下降和口干,未见4级晚期毒性。

要点

  • 按诱导化疗后肿瘤范围缩小靶体积并降低剂量,10年局部区域无复发生存率为89.0%。
  • 局部复发8例均为野内,区域复发6例中4例野内、1例边缘、1例野外。
  • 最常见晚期毒性为1-2级皮下纤维化、听力下降和口干,未见4级晚期毒性。

核心结论

  • 按诱导化疗后肿瘤范围缩小靶体积并对诱导化疗后肿瘤缩小区域降低剂量,可获得良好的长期局部区域控制,边缘及野外复发有限,晚期毒性轻微。

研究设计与样本

  • 前瞻性2期研究,纳入既往未治疗的局部晚期鼻咽癌患者112例,均接受2周期诱导化疗后同步放化疗。
  • 鼻咽原发灶大体肿瘤体积(GTVnx)和颈部淋巴结大体肿瘤体积(GTVnd)按诱导化疗后肿瘤范围勾画,分别接受68 Gy和62-66 Gy的全量治疗剂量。
  • 诱导化疗后原发肿瘤缩小区域纳入高危临床靶体积(CTV1),剂量降至60 Gy。

主要发现

  • 中位随访125.95个月,10年局部区域无复发生存率、无远处转移生存率和总生存率分别为89.0%、83.3%和75.9%。
  • 12例患者共出现8例局部复发和6例区域复发,8例局部复发均为野内,6例区域复发中4例野内、1例边缘、1例野外。
  • 诱导化疗后GTVnx、左侧GTVnd、右侧GTVnd、CTV1和低危临床靶体积(CTV2)的平均平均剂量分别为75.24、68.97、69.16、70.49和63.37 Gy。
  • 最常见晚期毒性为1-2级皮下纤维化、听力下降和口干,未见4级晚期毒性。

关键数值与推荐

  • GTVnx接受68 Gy,GTVnd接受62-66 Gy。
  • 诱导化疗后肿瘤缩小区域纳入CTV1,剂量为60 Gy。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the long-term locoregional control, failure patterns, and late toxicity after reducing the target volume and radiation dose in patients with locoregionally advanced nasopharyngeal carcinoma patients treated with induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT). METHODS AND MATERIALS: Previously untreated patients with locoregionally advanced nasopharyngeal carcinoma were recruited into this prospective study. All patients received 2 cycles of IC followed by CCRT. The gross tumor volumes of the nasopharynx (GTVnx) and the neck lymph nodes (GTVnd) were delineated according to the post-IC tumor extension and received full therapeutic doses (68 Gy and 62-66 Gy, respectively). The primary tumor shrinkage after IC was included in the high-risk clinical target volume (CTV1) with a reduced dose of 60 Gy. The locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), and overall survival (OS) were calculated using the Kaplan-Meier method. The location and extent of locoregional recurrences were transferred to pretreatment planning computed tomography for dosimetry analysis. RESULTS: There were 112 patients enrolled in this study. The average mean dose of post-GTVnx, post-GTVnd (left), post-GTVnd (right), post-CTV1, and post-low-risk clinical target volume (CTV2) was 75.24, 68.97, 69.16, 70.49, and 63.37 Gy, respectively. With a median follow-up of 125.95 months, the 10-year LRRFS, DMFS and OS were 89.0%, 83.3%, and 75.9%, respectively. There were 8 local recurrences and 6 regional recurrences in 12 patients. All 8 of the local recurrences were in-field; among the 6 regional recurrences, 4 were in-field, 1 was marginal, and 1 was out-field. The most common late toxicities were grade 1 to 2 subcutaneous fibrosis, hearing loss, and xerostomia. No grade 4 late toxicities were observed. CONCLUSIONS: Reduction of the target volumes according to the post-IC tumor extension and radiation dose to the post-IC tumor shrinkage could yield excellent long-term locoregional control with limited marginal and out-field recurrences and mild late toxicities.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Zhao C, Miao JJ, Hua YJ, et al. Locoregional Control and Mild Late Toxicity After Reducing Target Volumes and Radiation Doses in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy: 10-Year Results of a Phase 2 Study. Int J Radiat Oncol Biol Phys. 2019. PMID: 30954521. doi:10.1016/j.ijrobp.2019.03.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。